IXSBF (InNexus Biotechnology) Total Liabilities : $9.81 Mil (As of Mar. 2011)

View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Total Liabilities?

InNexus Biotechnology's Total Liabilities for the quarter that ended in Mar. 2011 was $9.81 Mil.

InNexus Biotechnology's quarterly Total Liabilities increased from Sep. 2010 ($8.64 Mil) to Dec. 2010 ($9.20 Mil) and increased from Dec. 2010 ($9.20 Mil) to Mar. 2011 ($9.81 Mil).

InNexus Biotechnology's annual Total Liabilities increased from Jun. 2008 ($1.52 Mil) to Jun. 2009 ($5.86 Mil) and increased from Jun. 2009 ($5.86 Mil) to Jun. 2010 ($8.26 Mil).

InNexus Biotechnology Total Liabilities Historical Data

The historical data trend for InNexus Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Total Liabilities Chart

InNexus Biotechnology Annual Data

Trend

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

Total Liabilities

Get a 7-Day Free Trial

0.21

2.26

1.52

5.86

8.26

InNexus Biotechnology Quarterly Data
	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11
Total Liabilities	Get a 7-Day Free Trial															7.96	8.26	8.64	9.20	9.81

InNexus Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

InNexus Biotechnology's Total Liabilities for the fiscal year that ended in Jun. 2010 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.255	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.26

Total Liabilities	=	Total Assets (A: Jun. 2010 )	-	Total Equity (A: Jun. 2010 )
	=	3.312	-	-4.942
	=	8.25

InNexus Biotechnology's Total Liabilities for the quarter that ended in Mar. 2011 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.541	+	(0.269	+	0.00099999999999956
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	9.81

Total Liabilities	=	Total Assets (Q: Mar. 2011 )	-	Total Equity (Q: Mar. 2011 )
	=	3.237	-	-6.575
	=	9.81

InNexus Biotechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

InNexus Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7

Website

http://www.ixsbio.com

InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology Headlines

No Headlines